Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
Hong Kong · Delayed Price · Currency is HKD 70.00
+5.30 (8.19%)
Sep 30, 2026, 4:08 PM HKT
HKG:2315 Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 57,576 | 23,585 | 3,395 | 4,785 | 10,245 | - | |
Market Cap Growth | 404.05% | 594.71% | -29.05% | -53.29% | - | - |
Enterprise Value | 57,167 | 23,859 | 3,562 | 4,682 | 10,003 | - |
Last Close Price | 70.00 | 35.30 | 8.50 | 11.98 | 25.65 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 70.58 | 122.37 | 95.11 | - | - | - |
Forward PE | 69.61 | 49.96 | - | - | - | - |
PS Ratio | 29.35 | 15.37 | 3.25 | 6.06 | 16.97 | - |
PB Ratio | 20.56 | 9.72 | 3.80 | 5.50 | 7.87 | - |
P/TBV Ratio | 20.69 | 9.99 | 4.13 | 5.73 | 8.12 | - |
P/FCF Ratio | 328.89 | 75.04 | 18.32 | - | - | - |
P/OCF Ratio | 116.42 | 57.24 | 15.10 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 29.14 | 15.55 | 3.41 | 5.93 | 16.57 | - |
EV/EBITDA Ratio | 90.96 | 67.88 | 13.92 | - | - | - |
EV/EBIT Ratio | 119.26 | 101.51 | 25.51 | - | - | - |
EV/FCF Ratio | 326.55 | 75.91 | 19.23 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.29 | 0.27 | 0.68 | 0.69 | 0.36 | 0.07 |
Debt / EBITDA Ratio | 1.25 | 1.70 | 2.14 | - | - | - |
Debt / FCF Ratio | 4.57 | 2.07 | 3.28 | - | - | - |
Net Debt / Equity Ratio | -0.15 | -0.46 | 0.20 | 0.14 | -0.20 | -0.39 |
Net Debt / EBITDA Ratio | -0.68 | -3.17 | 0.69 | -0.71 | 0.49 | 1.16 |
Net Debt / FCF Ratio | -2.37 | -3.54 | 0.96 | -0.54 | 0.42 | 0.86 |
Asset Turnover | 0.55 | 0.45 | 0.40 | 0.27 | 0.21 | 0.15 |
Inventory Turnover | 35.74 | 2.49 | 3.74 | 12.25 | 6.09 | 6.11 |
Quick Ratio | 2.79 | 2.05 | 1.20 | 1.01 | 1.25 | 1.55 |
Current Ratio | 3.42 | 2.31 | 1.53 | 1.25 | 1.52 | 1.96 |
Return on Equity (ROE) | 22.05% | 11.48% | 4.12% | -39.45% | -50.12% | -40.27% |
Return on Assets (ROA) | 8.64% | 4.30% | 3.37% | -6.94% | -14.81% | -14.02% |
Return on Invested Capital (ROIC) | 20.01% | 17.82% | 10.76% | -31.99% | -71.53% | -76.89% |
Return on Capital Employed (ROCE) | 13.50% | 7.60% | 7.00% | -15.60% | -27.60% | -28.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.73% | 0.82% | 1.05% | -8.82% | -6.64% | - |
FCF Yield | 0.30% | 1.33% | 5.46% | -4.68% | -6.00% | - |
Payout Ratio | 4.11% | 8.69% | 45.29% | - | - | - |
Buyback Yield / Dilution | -1.95% | 3.93% | -5.26% | -4.54% | -5.13% | -180.82% |